Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD1-Vaxx neoadjuvant vaccine study in operable MSI-high colorectal cancer
ISRCTN48890983Phase 2Terminated
- Sponsor
- University of Southampton
- Start
- Aug 2024
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label, single-arm trial of pd1-vaxx in colorectal cancer (CRC), sponsored by University of Southampton. Primary endpoint: Major pathological response. Started Aug 2024; status: terminated.
02
Drugs
pd1-vaxx
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ISRCTN48890983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN48890983.